Assets
(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | EGFR (activator) / HLA-A*02 (blocker)Cell therapy | Non-Small Cell Lung Cancer | |
| Phase 1/2 | CEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)Cell therapy | Non-Small Cell Lung Cancer | |
| Phase 1/2 | Mesothelin/MSLN (activator) / HLA-A*02 (blocker)Cell therapy | Non-Small Cell Lung Cancer | |
| Phase 1/2 | Mesothelin/MSLN (activator) / HLA-A*02 (blocker)Cell therapy | Non-Small Cell Lung Cancer |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.